An observational study in MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Columbia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in MELAS Syndrome with a site in United States — 6 open to participants now, 6 under way, 1 of them phase 3. MELAS Syndrome · United States.
Among the 21 studies in MELAS Syndrome with a site in United States, this one is the only one that started in 2004, is one of 5 observational ones, and was the 7th registered.
37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.
Browse MELAS Syndrome studies →6 of the 21 studies in MELAS Syndrome with a site in United States are open now. Recruiting first, the newest first:
Khondrion BV · Sites in United States, Denmark, France and 4 more countries
Ages 18+
Michio Hirano, MD · Sites in United States
Ages 18–80
Columbia University · Sites in United States, Canada
Healthy volunteers
Columbia University · Sites in United States
Healthy volunteers
George Washington University · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 MELAS Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 4 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 3 · Phase 4 1
First in 1978; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 27 across the 15 interventional studies, 300 across the 5 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
Columbia University has 3 studies filed under MELAS Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in MELAS Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in MELAS Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Carriers of the m.3242A>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a "Natural History Study" to monitor these conditions over time so that physicians and scientists can not only understand the problems that patients have, but work on developing treatments. The focus of the current work is to evaluate known mutation carriers of the m.3243A>G (mitochondrial DNA) and their maternal relatives (carrier status not a requirement for participation). Paternal relatives will serve as controls. This study involves no treatment.
The purpose of this study is to investigate the neurological and biochemical consequences of the m.3243 A>G mutation. Mitochondria are the powerhouses of the cell and are controlled by nuclear genetic material (DNA) and mitochondrial (mt) DNA. Mitochondrial DNA mutations impair mitochondrial function, and cause cellular energy failure. These mutations, when present in high abundance, cause neurological signs and symptoms that are clinically obvious. The investigators hypothesize that these mutations, when present in lesser abundance, will cause measurable alterations in the patient's neuropsychological profile and cerebral energy profile. This study does not involve any experimental or approved therapy. The investigators will evaluate the patient's condition with blood/urine tests, neurological exam, MRI/MRS, questionnaires, motor skills functioning, serum and urine biomarkers, and genetic testing.
Carriers of the m.3243A>G mitochondrial DNA point mutation, and their maternal relatives (carrier status documentation not required.). All patients suspected of having an mtDNA point mutation regardless of age, health status, gender, race, or ethnicity will be evaluated. The minimal age of entry into the study will be 4 years or older. We will also evaluate controls (often these are married in relatives).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Known carrier of a the m.3243 A>G mitochondrial mutation, ,or Maternally related to someone who carries the m.3243A>G mitochondrial mutation.
A family member who is not maternally related to someone who carries the m.3243A>G mitochondrial mutation
Exclusion Criteria:
m.3243 A\>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included
controls (people not maternally related to mutation carriers) Preference is for married in relatives
MRI/MRS
Evaluate structure and function in brain and muscle
Time frame: 2-3 years
Biomarkers
Evaluate various biomarkers of disease progression
Time frame: 2-3 years
Motor skills
6 minute walk test to evaluate motor skills
Time frame: 2-3 years
Cognitive function
Evaluate cognitive function through neuropsychological testing
Time frame: 2-3 years
Clinical symptoms
Evaluate clinical symptoms through medical history questionnaires and physical exam
Time frame: 2-3 years
Mutation load
Evaluate heteroplasmy through blood,urine and skin fibroblast evaluations
Time frame: 2-3 years
Plan to share: Yes — When applicable, manuscript(s) regarding data will be submitted for publication
Started Jul 2004 (actual). Primary completion is estimated for Jul 2026, 264 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.